Jeong A Park

Associate Professor

Inha University Hospital

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Immunology Immunology professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jeong A Park is an Associate Professor at Inha University Hospital in South Korea. His research primarily focuses on antibody-based cellular immunotherapy, targeting tumor vasculature to enhance T cell activity, and developing bispecific antibodies to overcome tumor heterogeneity. Recent publications include works on novel bispecific antibodies for neuroblastoma and osteosarcoma treatment, as well as studies on T cell engagement for cancer immunotherapy.

Articles (10)

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Ji Kyoung Park

Professor

Inje University - Busan Campus

SOUTH KOREA

View details

Eu Jeen Yang

Pusan National University Children’s Hospital

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jeong A Park

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

High-Risk Neuroblastoma Challenges and Opportunities for Antibody-Based Cellular Immunotherapy

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.

Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies.

Treatment Outcomes of Pediatric Acute Myeloid Leukemia in the Yeungnam Region: A Multicenter Retrospective Study of the Study Alliance of Yeungnam Pediatric Hematology–Oncology (SAYPH)

Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response.

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.

Targets and Antibody Formats for Immunotherapy of Neuroblastoma.

Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies.

Collaborators (2)

Ji Kyoung Park

Eu Jeen Yang

Make your next move.